1. Smiley D, Dagogo-Jack S, Umpierrez G (2008) Therapy insight: metabolic and endocrine disorders in sickle cell disease. Nat Clin Pract Endocrinol Metab 4(2):102–109
2. Bae HT, Baldwin CT, Sebastiani P, Telen MJ, Ashley-Koch A, Garrett M, Hooper WC, Bean CJ, DeBaun MR, Arking DE, Bhatnagar P, Casella JF, Keefer JR, Barron-Casella E, Gordeuk V, Kato GJ, Minniti C, Taylor J, Campbell A, Luchtman-Jones L, Hoppe C, Gladwin MT, Zhang Y, Steinberg MH (2012) Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood 120:1961–1962
3. Rees DC, Williams TN, Gladwin MT (2010) Sickle-cell disease. Lancet 376:2018–2031
4. Lettre G (2012) The search for genetic modifiers of disease severity in the hemoglobinopathies, Cold Spring Harb. Perspect. Med 2 (10) (2012) 1–12
5. Bauer DE, Kamran SC, Orkin SH (2012) Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders. Blood 120(15):2945–2953